• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cellular Dynamics, AstraZeneca partner on use of iPSC-derived human cells in drug discovery

Cellular Dynamics, AstraZeneca partner on use of iPSC-derived human cells in drug discovery

January 7, 2013
CenterWatch Staff

Cellular Dynamics International (CDI), a developer of next-generation stem cell technologies, signed a Center of Excellence agreement with global biopharmaceutical company AstraZeneca to accelerate the pace of drug discovery through the use of human induced pluripotent stem cell (iPSC) lines and tissue cells.

iPSC technology, based on reprogramming adult cells from a simple blood sample or a skin biopsy to a pluripotent stem cell state, shows promise in delivering robust human cell models of high utility in drug discovery and without the ethical concerns linked to the use of human embryonic stem cells.

AstraZeneca will take advantage of commercially available iCell products and CDI's recently launched MyCell products for iPSC reprogramming and differentiation, and the two parties will collaborate on the development of one or more novel cell types. AstraZeneca will purchase CDI's commercially available iCell products, including iCell Cardiomyocytes, iCell Neurons, iCell Endothelial Cells and iCell Hepatocytes, for use in their safety, discovery and regenerative medicine programs. Further, AstraZeneca will rely on CDI's novel MyCell products to genetically engineer and manufacture cells from specific patient groups for use as in vitro disease models. In addition, CDI will work in partnership with AstraZeneca toward development of new iPSC-derived cell types to enable novel discovery screening applications. Financial terms of the agreement were undisclosed.

"Increasingly, customers are recognizing CDI's focus and investment on industrializing the manufacture of iPSC-derived cells,” said Chris Parker, chief commercial officer of CDI. “Utilizing these standardized cellular tools enables customers like AstraZeneca to concentrate on developing therapies rather than manufacturing cell types."

Bob Palay, CEO of CDI, said, "This is the third Center of Excellence agreement we have entered into with a global pharma company, and these partnerships show customer recognition that leveraging CDI's technical expertise and resources can help accelerate their discoveries. We are excited that AstraZeneca shares our vision that iPSC technology can be transformative. The Center of Excellence agreements show CDI's leadership in developing best practices to employ human iPSCs to advance healthcare discoveries."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing